Institutet för Hälso- och
Sjukvårdsekonomi
Box 2127
SE-220 02 Lund
Besök: Råbygatan 2
Tel: 046-32 91 00
ihe[at]ihe.se

Ragnarson Tennvall Gunnel
dr i medicinsk vetenskap | civilekonom | fil kand | projektledare

Arbetsområden

Gunnel Ragnarson Tennvall har mer än 20 års erfarenhet av hälsoekonomiskt analysarbete. Hennes forskning är inriktad mot hälsoekonomiska analyser av läkemedel och annan medicinsk teknologi. Flertalet projekt genomförs i samarbete med kliniskt verksamma forskare. Gunnel disputerade vid medicinska fakulteten vid Lunds universitet 2001 med avhandlingen “The Diabetic foot – Costs, health economic aspects, prevention and quality of life”.

Pågående och nyligen avslutade projekt inkluderar analys av registerdata avseende exempelvis malignt melanom och aktinisk keratos. Utvärdering och analys av interventioner för behandling av sjukdomar inom dermatologiområdet och cancersjukdomar är andra aktuella arbetsområden. Andra intresseområden är mätning av livskvalitet och QALYs.

Gunnel har medverkat som hälsoekonom i arbetet med Socialstyrelsens Nationella riktlinjer för prostatacancer- och bröstcancersjukvård som publicerades 2007 och medverkar i den pågående uppdateringen av de Nationella riktlinjerna för bröst-, kolorektal- och prostatacancersjukvård.

Sedan 2001 är Gunnel medlem i EURODIALE, en europeisk forskargrupp inriktad på studier av diabetiker med fotkomplikationer.

Sjukdomsområden:
       •  Dermatologi, t ex psoriasis, atopisk dermatit, aktinisk keratos, 
          venösa bensår      
       •  Diabetes, särskilt fotkomplikationer 
       •  Onkologi, t ex bröstcancer, kolorektalcancer, prostatacancer, 
          malignt melanom 
       •  Smärttillstånd


Urval av publiceringar

Gudnadottir G, Ragnarson Tennvall G, Stalfors J & Hellgren J
Indirect costs related to caregivers’ absence from work after paediatric tonsil surgery
European Archives of Oto-Rhino-Laryngology 2017
Open Access


Ragnarson Tennvall G & Fasth A
Cord blood transplantation, a cost-effective alternative: a health-economic analysis of the National Swedish Cord Blood Bank
Bone Marrow Transplantation, 2017 Apr; 52 (4): 638-640

Hjalte F, Ragnarson Tennvall G, Welin K-O and Westerling D
Treatment of Severe Pain and Opioid-induced Constipation: An Observational Study of Quality of Life, Resource Use, and Costs in Sweden
Pain and Therapy, 2016; 5(8): 1-10

Lanbeck P, Ragnarson Tennvall G & Resman F
A cost analysis of introducing an infectious disease specialist-guided antimicrobial stewardship in an area with relatively low prevalence of antimicrobial resistance
BMC Health Services Research (2016) 16:311
Publicerad online: 27 juli 2016
Open Access


Olofsson S, Norrlid H, Karlsson E, Wilking U & Ragnarson Tennvall G
Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer e An observational study prospectively recording resource utilization in a Swedish healthcare setting
The Breast 2016; 29: 140-146

Cardell L-O, Olsson P, Andersson M, Welin K-O, Svensson J, Ragnarson Tennvall G & Hellgren J
TOTALL: high cost of allergic rhinitis—a national Swedish population-based questionnaire study
npj Primary Care Respiratory Medicine 2016; 26
Artikelnummer: 15082
Publicerad online: 4 februari 2016


Norrlid H, Hjalte F, Lundqvist A, Svensson Å & Ragnarson Tennvall G
Cost-effectiveness of Maintenance Treatment with a Barrier-strengthening Moisturizing Cream in Patients with Atopic Dermatitis in Finland, Norway and Sweden
Acta Derm Venereol 2016; 96: 173–176.
Läs mer och ladda ner artikeln »


Ragnarson Tennvall G., Norlin J.M., Malmberg I., Erlendsson A.M. & Hædersdal M.
Health related quality of life in patients with actinic keratosis – an observational study of patients treated in dermatology specialist care in Denmark
Health and Quality of Life Outcomes 2015; 13(111): 1-9

Ragnarson Tennvall G & Lundqvist A
Screening för livmoderhalscancer. Rekommendation och bedömningsunderlag. Bilaga: Värdet av populationsbaserad screening för livmoderhalscancer. Hälsoekonomisk analys av HPV-test och cytologi
Stockholm: Socialstyrelsen, 2015.
Artikelnummer: 2015-6-39


Öien RF, Forsell H & Ragnarson Tennvall G
Cost consequences due to reduced ulcer healing times – analyses based on the Swedish Registry of Ulcer Treatment
Int Wound J. 2015

Pickwell K, Siersma V, Kars M, Apelqvist J, Bakker K, Edmonds M, Holstein P, Jirkovská A, Jude E, Mauricio D, Piaggesi A, Ragnarson Tennvall G, Reike H, Spraul M, Uccioli L, Urbancic V, van Acker K, van Baal J & Schaper N
Predictors of lower-extremity amputation in patients with an infected diabetic foot ulcer
Diabetes Care. 2015; 38: 852-857

Steen Carlsson K, Hjalte F, Lundqvist A, Ragnarson Tennvall G, Häger Glenngård A, Nilsson S & Lundgren C medverkan i
Nationella riktlinjer Diabetesvård 2015. Stöd för styrning och ledning
Stockholm: Socialstyrelsen, 2015.
Artikelnummer: 2015-2-3


Norrlid H, Dahm P & Ragnarson Tennvall G
Evaluation of the cost-effectiveness of buprenorphine in treatment of chronic pain using competing EQ-5D weights
Scandinavian Journal of Pain 2015; 6: 24-30

Ragnarson Tennvall G, Hjalte F & Lundqvist A medverkan i
Nationella riktlinjer 2014. Bröst-, prostata-, tjocktarms- och ändtarmscancervård – Stöd för styrning och ledning
Stockholm: Socialstyrelsen, 2014.
Artikelnummer: 2014-4-2


Siersma V, Thorsen H, Holstein PE, Kars M, Apelqvist J, Jude EB, Piaggesi A, Bakker K, Edmonds M, Jirkovská A, Mauricio D, Tennvall GR, Reike H, Spraul M, Uccioli L, Urbancic V, van Acker K, van Baal J & Schaper NC.
Health-Related Quality of Life predicts major amputation and death, but not time to healing, in people with diabetes mellitus presenting with foot ulcers: the Eurodiale study
Diabetes Care 2014; 37(3): 694-700
Publicerad online 29 oktober 2013


Ragnarson Tennvall G, Hjortsberg C, Bjarnason A, Gniadecki R, Heikkilä H, Jemec GB, Kragballe K, Miller IM & Svensson A.
Treatment Patterns, Treatment Satisfaction, Severity of Disease Problems, and Quality of Life in Patients with Psoriasis in Three Nordic Countries
Acta Derm Venereol 2013; 93: 442-445

Siersma V, Thorsen H, Holstein PE, Kars M, Apelqvist J, Jude EB, Piaggesi A, Bakker K, Edmonds M, Jirkovska A, Mauricio D, Ragnarson Tennvall G, Reike H, Spraul M, Uccioli L, Urbancic V, van Acker K, van Baal J and Schaper NC
Importance of factors determining the low health-related quality of life in people presenting with a diabetic foot ulcer: the Eurodiale study
Diabetic Medicine 2013





Pickwell KM, Siersma VD, Kars M, Holstein PE, Schaper NC; Eurodiale consortium. Collaborators: Prompers L, Huiberts M, Schaper N, Apelqvist J, Bakker K, Edmonds M, Holstein P, Jude E, Jirkovská A, Mauricio D, Piaggesi A, Reike H, Spraul M, van Acker K, van Baal S, van Merode F, Uccioli L, Urbancic V, Ragnarson Tennvall G.
Diabetic foot disease: impact of ulcer location on ulcer healing
Diabetes Metab Res Rev. 2013; 29(5): 377-383

Svensson J, Lundberg J, Olsson P, Stjärne P & Tennvall GR
Cost-effectiveness of mometasone furoate nasal spray in the treatment of acute rhinosinusitis
Prim Care Respir J. 2012; 21(4): 412-8

Hjortsberg C, Bergman A, Bjarnsson A, Heikkilä H, Hjelmgren J, Svensson Å & Tennvall Ragnarson G
Are Treatment Satisfaction, Quality of Life, and Self-assessed Disease Severity Relevant Parameters for Patient Registries? Experiences from Finnish and Swedish Patients with Psoriasis
Acta Derm Venereol 2011; 91: 409–414

van Battum P, Schaper N, Prompers L, Apelqvist J, Jude E, Piaggesi A, Bakker K, Edmonds M, Holstein P, Jirkovska A, Mauricio D, Ragnarson Tennvall G, Reike H, Spraul M, Uccioli L, Urbancic V, van Acker K, van Baal J, Ferreira I & Huijberts M
Differences in minor amputation rate in diabetic foot disease throughout Europe are in part explained by differences in disease severity at presentation
Diabet Med. 2011 Feb; 28(2): 199-205

Hjalte F, Asseburg C, Tennvall G R
Cost-effectiveness of a barrier-strengthening moisturizing cream as maintenance therapy vs. no treatment after an initial steroid course in patients with atopic dermatitis in Sweden - with model applications for Denmark, Norway and Finland
Journal of the European Academy of Dermatology and Venereology, JEADV, 2010; 24(4): 474-480

Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, Edmonds M, Holstein P, Jirkovska A, Mauricio D, Tennvall GR, Reike H, Spraul M, Uccioli L, Urbancic V, Van Acker K, Van Baal J, Van Merode F & Schaper N.
Delivery of care to diabetic patients with foot ulcers in daily practice: results of the Eurodiale Study, a prospective cohort study
Diabetic Medicine 2008; 25: 700-707

Prompers L, Huijberts M, Schaper N, Apelqvist J, Bakker K, Edmonds M, Holstein P, Jude E, Jirkovska A, Mauricio D, Piaggesi A, Reike H, Spraul M, Van Acker K, Van Baal S, Van Merode F, Uccioli L, Urbancic V & Ragnarson Tennvall G.
Resource utilisation and costs associated with the treatment of diabetic foot ulcers. Prospective data from the Eurodiale Study
Diabetologia 2008; 51:1826-1834

Prompers L, Schaper N, Apelqvist J, Edmonds M, Jude E, Mauricio D, Uccioli L, Urbancic V, Bakker K, Holstein P, Jirlovska A, Piaggesi A, Ragnarson Tennvall G, Reike H, Spraul M, Van Acker K, Van Baal J, Van Merode F, Ferreira I, and Huijberts M.
Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE study
Diabetologia 2008; 51 (5): 747-755

Hjelmgren J, Svensson Å, Jörgensen ET, Lindemalm-Lundstam B & Ragnarson Tennvall G
Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data
British Journal of Dermatology (BJD) 2007; 156 (5): 913-921.
Erratum (BJD) 2008; 159: 994-995. 


Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, Edmonds M, Holstein P, Jirkovska A, Mauricio D, Ragnarson Tennvall G, Reike H, Spraul M, Uccioli L, Urbancic V, van Acker K, van Baal S, van Merode F & Schaper N.
High prevalence of ischemia, infection and serious co-morbidity in patients with diabetic foot disease in Europe. Baseline results from the EURODIALE study
Diabetologia 2007; 50 (1): 18-25

Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, Edmonds M, Holstein P, Jirkovska A, Mauricio D, Tennvall GR, Reike H, Spraul M, Uccioli L, Urbancic V, van Acker K, van Baal J, van Merode F & Schaper N.
Optimal organization of health care in diabetic foot disease: introduction to the Eurodiale study
Int J Low Extrem Wounds 2007; 6 (1): 11-17

Ragnarson Tennvall G, Hjelmgren J & Öien R
The cost of treating hard-to-heal venous leg ulcers: results from a Swedish survey
World Wide Wounds, 2006, November.
www.worldwidewounds.com


Ragnarson Tennvall G, Hjelmgren J & Malmberg L
Under what conditions is feedback microwave thermotherapy (ProstaLund Feedback Treatment) cost-effective in comparison with alpha-blockade in the treatment of benign prostatic hyperplasia and lower urinary tract symptoms?
Scandinavian Journal of Urology and Nephrology 2006;40:495-505

Boulton A J M, Vileikyte L, Ragnarson Tennvall G & Apelqvist J. The global burden of diabetic foot disease. Lancet 2005; 366(12):1719-24.

Ragnarson Tennvall G & Hjelmgren J. Behandling av venösa bensår, kostsamt för sjukvård och samhälle. Läkartidningen 2005; 102(42): 3027-3029.

Hjelmgren J, Persson U & Ragnarsson Tennvall G. Local treatment pattern versus trial-based data: A cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden. American Journal of Therapeutics 2005; 12(5): 425-430.

Ragnarson Tennvall G. Economic factors. In Bakker K, Foster A, van Houtum W, Riley P (Eds). Put feet first prevent amputations. Diabetes and foot care. IDF, International Diabetes Federation, Brussels, 2005.

Ragnarson Tennvall G & Hjelmgren J. Annual costs of treatment for venous leg ulcers in Sweden and the United Kingdom.
Wound Repair and Regeneration 2005;13 (1):13-18.

Ragnarson Tennvall G & Apelqvist J. Health economic consequences of diabetic foot lesions. Clinical Infectious Diseases 2004;39: S132-9.

Ragnarson Tennvall G, Andersson K, Bjellerup M, Hjelmgren J & Öien R. Venösa bensår kan behandlas både bättre och billigare. Beräkning av årliga kostnader baserad på en enkätstudie. Läkartidningen 2004; 101: 1506-1513.

Fyhr, A., Jendteg, S., Ragnarson Tennvall, G., Cavallin-Ståhl, E. & Wain, R. Costs of preparing cytotoxic drugs by nurses on hospital wards or by pharmcists in preparation centres. Journal of Social and Administrative Pharmacy 2001:18(5);193-197.

Ragnarson Tennvall G. The diabetic foot – Costs, health economic aspects, prevention, and quality of life. Doktorsavhandling, Lunds Universitet, 2000.

Ragnarson Tennvall G & Apelqvist J. Prevention of diabetes-related foot ulcers and amputations – A cost-utility analysis based on Markov model simulations. Diabetologica 2001:44;2007-2087.

Ragnarson Tennvall G, Apelqvist J. Health-related quality of life in patients with diabetes mellitus and foot ulcers. Journal of Diabetes and Its Complications 2000: 14; 235-241.

Ragnarson Tennvall G, Apelqvist J, Eneroth M. Costs of deep foot infections in patients with diabetes mellitus. Pharmacoeconomics, 2000: 18(3); 225-238

Ragnarson Tennvall G, Apelqvist J, Eneroth M. The inpatient care of patients with diabetes mellitus and foot ulcers. A validation study of the correspondence between medical records and the Swedish Inpatient Registry with the consequences for cost estimations. Journal of Internal Medicine 2000: 248; 397-405.

© IHE 2017